Herbert L. Heyneker

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

zuChem, Inc. manufactures and supplies glycochemicals for the pharmaceutical, food and related industries. Its products include natural polyols, rare sugars and carbohydrates. Its glycochemicals are key components of many drugs and drug candidates as well as many specialty food ingredients. The company was founded by David C. Demirjian in 2001 and is headquartered in Chicago, IL.

Splash Beverage Group, Inc. manufactures healthy drinks. Its brands include TapouT and Salt Tequila. The company is headquartered in Fort Lauderdale, FL.

Genomatica, Inc. designs and develops biotechnology products. It offers metabolic engineering for renewable production of commodity chemicals. The company was founded by Bernhard O. Palsson and Christophe H. Schilling in 1998 and is headquartered in San Diego, CA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA.

Covance Biotechnology Services, Inc. develops pharmaceutical products. The company offers two microbiology laboratories, one for mycoplasma analysis, and a second for molecular biology. It provides services to biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, and gene therapy products. The company was founded by Richard J. Hawkins, V. Bryan Lawlis, and John A. Scarlett in 1995 and is headquartered in Princeton, NJ.

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Biosanapharma BV is a Dutch pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Leiden, Netherlands. The CEO of the company is Ard Tijsterman.

Aglaia Management BV is an independent venture capital investment firm headquartered in Bilthoven, the Netherlands. In 2003, Aglaia was co-founded by Mark Krul and Karl Rothweiler.

Pepscope BV is a company based in Utrecht, Netherlands that develops and provides advanced customer-focused protein analysis services and products. The Dutch company aims to make kinase inhibitors better therapeutics by providing unique insights into their functioning through quantitative profiling of the kinome in cells and tissues. Pepscope offers a unique, targeted mass-spectrometry-based, multiplexed, endogenous kinase activity profiling technology for clinical samples. Recently, Pepscope announced a 4.3-million-euro funding round to further develop and commercialize their lead product QuantaKinome™, which provides direct insights into the activities of hundreds of protein kinases simultaneously inside the cells of diseased tissues. Pepscope offers QuantaKinome™ to the pharmaceutical industry and academic researchers to improve the discovery and development of drugs. The company was founded by Jos Joore, Hans Brouwer, and Anna Ressa, with Anna Ressa serving as the CEO since incorporation.

Part of Novartis AG, Novartis, Inc. is a company based in San Francisco.

Casebia Therapeutics LLC discovers, develops, and commercializes gene-editing therapeutics to treat the genetic causes of bleeding disorders and autoimmune disease. The joint venture company is based in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA.

Mascoma Corp. develops technology for abundant biomass conversion. The firm operates through its bioprocessing technology platform, develops bioengineered yeasts and other microorganisms. It also designs and manufactures equipment that processes cellulosic biomass for further biological or chemical conversion. The company was founded by Lee R. Lynd, Charles E. Wyman and Robert J. Johnsen in 2005 and is headquartered in Waltham, MA.

Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands.

Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.